Articles tagged with: Maintenance Therapy

Opinion»

[ by | Feb 21, 2013 12:44 pm | 29 Comments ]
ME vs. MM: Life After Dex

Perhaps the title of this column more appropriately should be “Life After CRD,” since I’ve now completed 24 cycles of Kyprolis (carfilzomib), Revlimid (lena­lido­mide), and dexa­metha­sone (Decadron), commonly referred to as CRD, as part of a clinical trial for newly diagnosed patients.

However, since dexa­metha­sone seemed to be the predominate source of my side effects, and be­cause I liked the play on words, I went with the title as shown.

So, I’ve completed the clinical trial, I’ve reached stringent complete response, and I’ve won …

Read the full story »

Opinion»

[ by | Dec 4, 2012 1:25 pm | 24 Comments ]
Sean’s Burgundy Thread: Wednesdays With Murray

While I am not so much a creature of habit, my Wednesday afternoon activities over the last three years have been pretty much chiseled in stone.

At around noon on a typical Wednesday, I drop everything that I’m doing, jump into my car, drive across the Kimberling City Bridge that sits perched 30 feet above beautiful Table Rock Lake, and then wind my way through the rolling Ozark hills and picturesque hollows toward the nationally known tourist and entertainment small city of Branson, Missouri.

Upon arrival at my destination, I …

Read the full story »

News»

[ by | Aug 29, 2012 3:43 pm | Comments Off ]
Velcade-Thalidomide And Velcade-Prednisone May Be Effective As Maintenance Therapy For Elderly Myeloma Patients

Results of a recent Spanish study suggest that elderly multiple myeloma patients who receive Velcade plus thalidomide or Velcade plus pred­nisone as maintenance therapy achieve deeper responses following initial therapy with Velcade-based treatment regimens.

In addition, elderly myeloma patients who receive Velcade plus thalido­mide as maintenance therapy may achieve better treatment outcomes and longer survival rates than patients who receive Velcade plus pred­nisone as maintenance therapy.

“In our trial, VT [Velcade plus thalidomide] was slightly superior to VP [Velcade plus prednisone] in response rate and outcome, but the dif­ferences didn’t …

Read the full story »

News»

[ by | Aug 21, 2012 10:40 am | 2 Comments ]
Revlimid Maintenance Therapy Gets NCCN Vote Of Confidence

The National Comprehensive Cancer Network (NCCN) has updated its guide­lines for the treatment of multiple myeloma, and the new guidelines will be interpreted by many as a vote of confidence for Revlimid maintenance therapy.

The NCCN guidelines are followed closely by physicians and by many U.S. health insurance companies, which frequently use them when making reim­burse­ment decisions about different cancer treatments.

The guidelines are comprised of recommendations based on the results of recent clinical trials and ongoing scientific research.  A panel of specialists within the myeloma field is responsible for …

Read the full story »

News»

[ by | Aug 20, 2012 11:36 am | Comments Off ]
Donor Stem Cell Transplantation Plus Revlimid Maintenance May Be Effective For Relapsed / Refractory Multiple Myeloma

Results of a recent, small German study show that donor stem cell trans­plan­tation followed by Revlimid maintenance therapy may be feasible in heavily pretreated relapsed or refractory multiple myeloma patients.

“For younger and fit patients, [donor] stem cell transplantation followed by maintenance therapy with [Revlimid] is a reasonable treatment option for patients who have already relapsed [after an autologous stem cell transplant],” said Dr. Nicolaus Kröger of the University Hospital Hamburg-Eppendorf in Germany and lead investigator of the study.

Dr. Philip McCarthy of the Roswell Park Cancer Institute in Buffalo, …

Read the full story »